Labcorp Holdings Inc. executive stock transaction reports
During the week of November 4, 2026, to November 10, 2026, executives and former managers at Labcorp Holdings Inc. filed notices regarding company stock transactions, including actual sales and proposed sales.
Key points
- Bryan T. Vaughn, executive vice president and president of diagnostics, reported the sale of 306 shares on November 3, 2026, in a filing dated November 5, 2026.
- Former manager Megan D. Bailey filed a notice on November 4, 2026, of a proposed sale of 3,035 shares, which she acquired that same day through a stock option exercise.
Insider transactions
Bryan T. Vaughn, executive vice president and president of diagnostics, reported the sale of 306 shares on November 3, 2026, in a filing dated November 5, 2026. The transaction was made under a 10b5-1 plan, a preset selling schedule executives set up in advance.
Proposed sales (Form 144), by insider
Notice of proposed stock sales
Former manager Megan D. Bailey filed a notice on November 4, 2026, of a proposed sale of 3,035 shares, which she acquired that same day through a stock option exercise.
Executive Brian J. Caveney reported a proposed sale of 2,000 shares on November 10, 2026. He acquired these shares between 2021 and 2025 through restricted stock vesting, where company shares are granted as employee compensation.
Next steps for investors
Shareholders should monitor future transaction reports to confirm if the proposed sales filed by executives actually occurred.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Labcorp
A notification in your browser or on your phone when we publish about Labcorp. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
